iRadimed Corp. (NASDAQ:IRMD)’s share price dropped 3.7% during trading on Thursday . The company traded as low as $18.47 and last traded at $18.56, with a volume of 60,690 shares. The stock had previously closed at $19.27.

IRMD has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded iRadimed Corp. from a “hold” rating to a “strong-buy” rating and set a $19.00 price objective on the stock in a research note on Wednesday, May 4th. Roth Capital dropped their price objective on iRadimed Corp. from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, April 4th.

The stock has a market cap of $211.33 million and a PE ratio of 29.03. The stock’s 50-day moving average is $20.59 and its 200 day moving average is $18.52.

iRadimed Corp. (NASDAQ:IRMD) last released its earnings results on Friday, July 29th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.03. The firm had revenue of $9.90 million for the quarter, compared to the consensus estimate of $9.60 million. iRadimed Corp.’s revenue for the quarter was up 30.3% on a year-over-year basis. During the same quarter last year, the company posted $0.16 EPS. Equities research analysts anticipate that iRadimed Corp. will post $0.89 EPS for the current fiscal year.

In other iRadimed Corp. news, Director Monty K. Allen sold 2,100 shares of the stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $20.44, for a total transaction of $42,924.00. Following the completion of the transaction, the director now owns 4,375 shares in the company, valued at approximately $89,425. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

An institutional investor recently raised its position in iRadimed Corp. stock. GSA Capital Partners LLP boosted its position in iRadimed Corp. (NASDAQ:IRMD) by 174.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 50,203 shares of the company’s stock after buying an additional 31,901 shares during the period. GSA Capital Partners LLP owned approximately 0.45% of iRadimed Corp. worth $1,407,000 as of its most recent filing with the SEC.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.